Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity

Promatix Biosciences Ltd (Promatix), an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, today presented positive ...
FOX8 Cleveland

Creative Diagnostics Announces New Reagents for Bioanalysis of Antibody Drug Conjugates

NEW YORK, UNITED STATES, July 19, 2023/ EINPresswire.com / -- Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced a series of new reagent ...
Nasdaq

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

This novel approach utilizes cysteine-engineered antibodies which allows for the development of uniform and homogenous ADCs with precise control of the drug to antibody ratio (DAR). The drug-payload, ...
Drug Target Review

Bispecific EGFR/EphA2-targeting ADC shows promise in colorectal cancer

PBS293-MMAE targets EGFR and EphA2, two proteins shown to be co-expressed in colorectal cancer cells. While EGFR is a clinically validated target in colorectal cancer, therapeutic antibodies such as ...
Business Wire

MBrace Therapeutics Presents Trial in Progress Poster for Lead Antibody-Drug Conjugate Program at 2024 ASCO Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage oncology company developing novel antibody-drug conjugates (ADCs) against solid tumor targets, today announced that ...
Nasdaq

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First ...

Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses All assessable nectin-4 positive study participants with mUC and cervical cancer ...